Edition:
United Kingdom

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

7.87USD
25 Apr 2018
Change (% chg)

$-0.01 (-0.13%)
Prev Close
$7.88
Open
$7.86
Day's High
$7.94
Day's Low
$7.86
Volume
17,377
Avg. Vol
22,247
52-wk High
$8.75
52-wk Low
$4.60

Chart for

About

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1)... (more)
No analyst recommendations are available for .

Overall

Beta: 0.10
Market Cap(Mil.): $446.97
Shares Outstanding(Mil.): 57.01
Dividend: --
Yield (%): --

Financials

  SVA.OQ Industry Sector
P/E (TTM): 24.31 29.65 32.31
EPS (TTM): 0.32 -- --
ROI: 20.14 13.36 12.97
ROE: 15.29 15.09 14.84

BRIEF-Sinovac Amends Shareholder Rights Plan

* SINOVAC BIOTECH LTD - ‍AMENDMENT EXTENDS EXPIRATION OF SHAREHOLDER RIGHTS PLAN FROM MARCH 27 TO MARCH 27, 2019​ Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Sinovac Provides Update On Going Private Transaction

* SINOVAC BIOTECH - EXPECTS TO FILE AMENDED GOING-PRIVATE STATEMENT, INCLUDING A DEFINITIVE PROXY STATEMENT AS AN EXHIBIT, WITH U.S. SEC IN DUE COURSE Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Sinovac Biotech Receives Positive Decision On Hepatitis A Vaccine From WHO

* SINOVAC BIOTECH RECEIVES POSITIVE DECISION ON ITS HEPATITIS A VACCINE FROM WORLD HEALTH ORGANIZATION

22 Dec 2017

BRIEF-Sinovac Biotech Announces Update On Nasdaq Matters

* SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​ Source text for Eikon: Further company coverage:

30 Nov 2017

BRIEF-Sinovac reports Q4 earnings per share $0.08

* Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results

22 Nov 2017

BRIEF-Sinovac Biotech receives delisting determination letter from Nasdaq

* Sinovac Biotech announces receipt of delisting determination letter from Nasdaq Source text for Eikon: Further company coverage:

03 Nov 2017

Competitors

Earnings vs. Estimates